Top

Published in:

01-11-2002 | Original Article

Biochemotherapy of metastatic malignant melanoma. On down-regulation of CD28

Authors: Annika Håkansson, Leif Håkansson, Bertil Gustafsson, Lennart Krysander, Björn Rettrup, Dirk Ruiter, Monique R. Bernsen

Published in: Cancer Immunology, Immunotherapy | Issue 9/2002

Title: Biochemotherapy of metastatic malignant melanoma. On down-regulation of CD28
Authors: Annika Håkansson
Leif Håkansson
Bertil Gustafsson
Lennart Krysander
Björn Rettrup
Dirk Ruiter
Monique R. Bernsen
Publication date: 01-11-2002
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 9/2002
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-002-0304-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 9/2002

The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy

Neurotransmitters are regulators for the migration of tumor cells and leukocytes

Induction of cytotoxicity against autologous tumour cells by interleukin-12:evidence for intrinsic anti-tumor immune capacity in curatively resected gastrointestinal tumour patients

Adhesion of lymphocytes to bladder cancer cells: the role of the αEβ7 integrin

Accumulation of CD45RO+ cells in peritoneal carcinomatous fluid favours survival of ovarian carcinoma patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer